Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C.
Publication
, Journal Article
Kelsey, MD; Newby, LK
Published in: Ann Intern Med
August 2022
Hao Q, Aertgeerts B, Guyatt G, et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. BMJ. 2022;377:e069066. 35508320.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
August 2022
Volume
175
Issue
8
Start / End Page
JC86
Location
United States
Related Subject Headings
- Proprotein Convertase 9
- PCSK9 Inhibitors
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Humans
- General & Internal Medicine
- Ezetimibe
- Cholesterol, LDL
- Cardiovascular Diseases
- Anticholesteremic Agents
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kelsey, M. D., & Newby, L. K. (2022). Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C. Ann Intern Med, 175(8), JC86. https://doi.org/10.7326/J22-0060
Kelsey, Michelle D., and L Kristin Newby. “Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C.” Ann Intern Med 175, no. 8 (August 2022): JC86. https://doi.org/10.7326/J22-0060.
Kelsey MD, Newby LK. Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C. Ann Intern Med. 2022 Aug;175(8):JC86.
Kelsey, Michelle D., and L. Kristin Newby. “Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C.” Ann Intern Med, vol. 175, no. 8, Aug. 2022, p. JC86. Pubmed, doi:10.7326/J22-0060.
Kelsey MD, Newby LK. Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C. Ann Intern Med. 2022 Aug;175(8):JC86.
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
August 2022
Volume
175
Issue
8
Start / End Page
JC86
Location
United States
Related Subject Headings
- Proprotein Convertase 9
- PCSK9 Inhibitors
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Humans
- General & Internal Medicine
- Ezetimibe
- Cholesterol, LDL
- Cardiovascular Diseases
- Anticholesteremic Agents
- 3202 Clinical sciences